Caroline Seymour

Managing Editor, OncLive®
Caroline Seymour is your initial point of contact for the OncLive® podcast, OncLive On Air™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com​

Articles

PDUFA Date Set for 3-Month Variation of Leuprolide Mesylate in Advanced Prostate Cancer

January 13th 2025

The FDA has set the PDUFA date for the 3-month, 21-mg variation of leuprolide mesylate in advanced prostate cancer for August 29, 2025.

Dato-DXd Receives FDA Priority Review in Pretreated EGFR-Mutated NSCLC

January 13th 2025

The BLA for Dato-DXd in locally advanced or metastatic EGFR-mutated NSCLC has been accepted and granted priority review by the FDA.

Adjuvant Cemiplimab Improves DFS in High-Risk Cutaneous Squamous Cell Carcinoma

January 13th 2025

Adjuvant therapy with cemiplimab improved DFS vs placebo in patients with high-risk cutaneous squamous cell carcinoma after surgery.

BTK Degraders Look to Fill Unmet Need for Patients With Pretreated B-Cell Malignancies

January 12th 2025

Michael T. Tees, MD, MPH, describes how BTK degraders represent a promising class of agents, highlighting the agent AC676 that is currently under evaluation.

Dr Piotrowska on Treatment Sequencing Decisions in HER2-Mutated NSCLC

January 10th 2025

Zosia Piotrowska, MD, MHS, discusses disease factors that guide treatment decision-making and sequencing for patients with HER2-mutated NSCLC.

Abenacianine Wins FDA Fast Track Designation for Tumor Visualization in the Lung

January 10th 2025

Data from a phase 2 trial demonstrated that abenacianine is a safe investigational tumor-targeted fluorescent imaging agent for tumors in the lung.

Axatilimab Shakes Up cGVHD Treatment and Looks to Move to Earlier Line in Paradigm

January 10th 2025

Christopher Graham, MD, details how axatilimab has changed the care of cGVHD and highlights considerations with axatilimab, belumosudil, and ruxolitinib.

BBO-8520 Receives FDA Fast Track Designation in KRAS G12C–Mutated Metastatic NSCLC

January 10th 2025

BBO-8520 has received FDA fast track designation in previously treated KRAS G12C–mutated metastatic non–small cell lung cancer.

Subcutaneous Isatuximab Plus Pd Meets Coprimary End Points, Proves Noninferior to IV Administration in R/R Multiple Myeloma

January 9th 2025

Subcutaneous isatuximab plus Pd led to a noninferior ORR and observed concentration before dosing at steady state vs IV isatuximab plus Pd in RRMM.

Durvalumab Plus Vaccine Therapy Elicits ‘Encouraging’ DFS in BCG-Unresponsive NMIBC

January 9th 2025

Durvalumab plus vaccine therapy demonstrated evidence of preliminary antitumor activity without substantial additive toxicity in BCG-unresponsive NMIBC.

Multidisciplinary Collaboration Is Crucial in Managing Ocular Toxicities of Mirvetuximab Soravtansine in Gynecologic Tumors

January 8th 2025

Rebecca Arend, MD, and Kathryn Lyle, CRNP, discuss their approach to managing ocular and other treatment-related toxicities associated with mirvetuximab soravtansine.

FDA Issues Draft Guidance for Accelerated Approval Confirmatory Clinical Trials

January 8th 2025

The FDA released a draft guidance document detailing their interpretation of when a confirmatory clinical trial for an accelerated approval is underway.

Sunvozertinib Under FDA Priority Review for NSCLC With EGFR Exon 20 Insertion Mutations

January 7th 2025

The FDA has granted priority review to sunvozertinib for advanced/metastatic NSCLC with EGFR exon 20 insertion mutations after progression on chemotherapy.

Amivantamab Plus Lazertinib Improves OS in EGFR-Mutant Advanced NSCLC

January 7th 2025

Amivantamab plus lazertinib prolonged overall survival vs osimertinib as first-line therapy in locally advanced or metastatic, EGFR-mutant NSCLC.

Imetelstat Plus Ruxolitinib Demonstrates Tolerable Safety Profile in Myelofibrosis

January 6th 2025

Imetelstat plus ruxolitinib showed early tolerability and efficacy in patients with intermediate and high-risk myelofibrosis.

Critical Recent NCCN Guideline Updates Affect Dozens of Malignancies

December 31st 2024

Experts detail how recent NCCN guideline changes in dozens of tumor types are affecting their practices, and we gather all the NCCN updates in a slideshow.

How a Never-Wavering Enthusiasm Changed Lung Cancer Care for the Better

December 30th 2024

As a female leader in a competitive oncology field, Solange Peters, MD, PhD, pushed through the barriers— climbed over them—and completely transformed lung cancer care with her collaborative spirit.

Preparation is Key to Tackle the Transition from Fellow to Attending Physician

December 29th 2024

A lymphoma hematologist/oncologist who recently transitioned from a fellow to an attending physician shares his experience with the change and tips for fellows.

Community Practice Training During Fellowship Often Falls Short

December 28th 2024

A hematology fellow discusses findings from 2 surveys he coauthored, which sought to identify gaps in community practice training during hematology/oncology fellowship.

Allosteric Inhibitors Targeting PIK3CA May Reduce Treatment Toxicities in Breast Cancer

December 26th 2024

Felipe Batalini, MD, and Alberto Montero, MD, MBA, CPHQ, detail how allosteric inhibitors targeting PIK3CA such as STX-478 may reduce toxicities seen with orthosteric inhibitors.

NEXT PAGE
PREVIOUS PAGE
x